Skip to main content

Drug Interactions between ocrelizumab and Recombivax HB Adult

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

hepatitis B adult vaccine ocrelizumab

Applies to: Recombivax HB Adult (hepatitis b adult vaccine) and ocrelizumab

MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. In a study in adults aged 18 to 55 years with relapsing forms of multiple sclerosis (MS), vaccination with several non-live vaccines in 68 subjects receiving ocrelizumab at the time of vaccination and 34 subjects not receiving ocrelizumab, revealed attenuated antibody titers in those receiving treatment with ocrelizumab. The vaccines tested included tetanus toxoid-containing vaccine, pneumococcal polysaccharide, pneumococcal conjugate vaccines, and seasonal inactivated influenza vaccines. Additionally, because therapy with ocrelizumab causes a depletion of B-cells, a decrease or suboptimal immunologic vaccine response may be expected if immunization occurs before B-cells counts have recovered. Pharmacodynamic data has shown the median time to B-cell repletion following discontinuation of ocrelizumab is 72 weeks (range 27 to 175 weeks). For infants of mothers who have been exposed to ocrelizumab during pregnancy, there is a potential for depletion of B cells in their infants.

MANAGEMENT: Ocrelizumab therapy may interfere with the effectiveness of non-live vaccines. The immunization status of patients should be reviewed prior to initiating therapy with ocrelizumab and recommended immunizations with non-live vaccines completed at least 2 weeks prior to initiating therapy (some authorities have recommended at least 6 weeks). Annual influenza vaccines are recommended for patients being treated with ocrelizumab. For infants of mothers exposed to ocrelizumab during pregnancy, non-live vaccines may be administered as indicated, however, adequacy of vaccine response should be assessed; this may include a consultation with a qualified specialist or measurement of vaccine-induced response titers to verify that a protective immune response has been mounted.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Ocrevus (ocrelizumab)." Genentech (2017):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer